SCHEMBL30859786

SCHEMBL30859786

C[C@@H](NC(=O)OC(C)(C)C)C(=O)N1CCN(c2ncc(C(F)(F)F)cn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TIPARP Q7Z3E1 12/20 0.46
PARP12 Q9H0J9 3/20 0.46
TNKS2 Q9H2K2 3/20 0.46
PARP2 Q9UGN5 3/20 0.46
TNKS O95271 2/20 0.46
PARP10 Q53GL7 2/20 0.46
SLC6A9 P48067 1/20 0.44
HRH2 P25021 2/20 0.43
HRH1 P35367 2/20 0.43
PARP14 Q460N5 2/20 0.43
PARP11 Q9NR21 2/20 0.43
PARP1 P09874 1/20 0.43
CYP2C9 P11712 1/20 0.43
PARP16 Q8N5Y8 1/20 0.43
PARP4 Q9UKK3 1/20 0.43
PARP3 Q9Y6F1 1/20 0.43
ACACB O00763 1/20 0.42
GPR119 Q8TDV5 1/20 0.42
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30860030 1.00 TIPARP (0.46) TIPARPPARP12TNKS2PARP2TNKS
SCHEMBL30546333 0.85 TIPARP (0.48) TIPARPPARP12TNKS2PARP2TNKS
SCHEMBL30549218 0.83 TIPARP (0.42) TIPARPPARP12TNKS2PARP2TNKS
SCHEMBL25699748 0.81 TIPARP (0.56) TIPARPPARP12TNKS2PARP2TNKS
SCHEMBL30859909 0.81 TIPARP (0.44) TIPARPPARP12TNKS2PARP2PARP14
SCHEMBL21521091 0.81 GPR119 (0.60) TIPARPGPR119PPARGPPARDPPARA
SCHEMBL30859841 0.81 TIPARP (0.43) TIPARPPARP12TNKS2PARP2PARP14
SCHEMBL21521521 0.80 TIPARP (0.62) TIPARPPARP12TNKS2PARP2PARP14
SCHEMBL21521520 0.80 TIPARP (0.62) TIPARPPARP12TNKS2PARP2PARP14
SCHEMBL30549224 0.80 TIPARP (0.45) TIPARPPARP12TNKS2PARP2TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 CN disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 TIPARP 1314/4885PARP12 6/4885TNKS2 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.